Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab
2016 ASCO Annual MeetingJonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss mutation burden—its role in response to treatment with PD-L1 immunotherapy and its impact on progression-free survival and overall survival, as well as the link between intrinsic expression subtypes and treatment outcome with atezolizumab (Abstract 104).
Related Videos
Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis
Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Gideon Michael Blumenthal, MD, of the US Food and Drug Administration, discuss milestone analyses w...
James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma
James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Ab...
Ghassan K. Abou-Alfa, MD, on Sorafenib and Doxorubicin for Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings of this phase III study of sorafenib plus doxorubicin versus sorafenib in patients with a...
Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial
Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplasti...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line t...
